

How Can You Access Personalized Care?

- Ensure your doctor has experience treating endometrial cancer. Consider a second opinion with a specialist.
- Request all essential testing, including biomarker testing, and discuss how the results may impact prognosis and therapy options.
- Understand ALL of the treatments available to you including clinical trials.
- Make sure to have a friend or loved one present during discussions, so you can talk about the information later and feel confident when making care decisions.
- Don't hesitate to share your opinion and to ask questions about available treatment options. Remember, YOU should be at the center of your endometrial cancer care.

Glossary Terms

Biomarker Testing (molecular testing): Laboratory testing that identifies certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. In cancer, it may also be used to evaluate treatment or to make a prognosis.

CDK (cyclin-dependent kinase) Inhibitor: A targeted treatment that inhibits the function of CDKs.

Immunotherapy: Type of therapy that harnesses one's own immune system to help the body fight cancer, infection, and other diseases.

Microsatellite Instability (MSI): Prognostic marker found in endometrial and colorectal cancers. The presence of MSI may help determine a treatment plan.

PARP Inhibitors: A type of targeted treatment that inhibits the enzyme poly (ADP-ribose) polymerase.

Personalized Medicine: Also called precision medicine, is a type of care that is based on the genetic makeup and individual characteristics of a patient's disease.

Somatic Mutations: Mutations that can occur in any of the cells of the body but are not hereditary. These mutations may, in some cases, cause cancer or other diseases.

Standard of Care: An established guideline that is consensus among experts as the most appropriate and/or effective treatment for a specific type and stage of cancer.

Targeted Therapy: A type of personalized medicine that works by blocking specific mutations and by preventing cancer cells from growing and dividing, without affecting normal cells.

Vaginal Brachytherapy: A radioactive source enclosed in a cylinder is temporarily inserted into the vagina to deliver radiation therapy.

Biomarkers That May Impact Treatment Options Include:	Treatment Decision Factors Include:
Microsatellite instability (MSI high)Mismatch repair defects (dMMR)	 Baseline health and function of a patient, including their existing medical conditions
HER-2 mutation	Pathology results
MTOR mutationEstrogen or progesterone receptors	Surgical staging resultsMicrosatellite status

Evolve Endometrial Cancer is brought to you by the Patient Empowerment Network. It is made possible through support from Karyopharm, Merck, and through generous donations from people like you.



question@powerfulpatients.org www.powerfulpatients.org



@power4patients